130 results about "Vaccine virus" patented technology

The invention relates to a method for inducing protection against the 4 serotypes of dengue fever in a patient, comprising:(a) the administration of a monovalent vaccine comprising a vaccinal virus of a first serotype of dengue fever, and(b) the administration of a tetravalent vaccine comprising vaccinal viruses of the four serotypes of dengue fever,in which administration (b) is made between at least 30 days and not more than 12 months following the first administration (a).

The invention relates to a method for inducing protection against the 4 serotypes of dengue fever in a patient, comprising:(a) the administration of a monovalent vaccine comprising a vaccinal virus of a first serotype of dengue fever, and(b) the administration of a tetravalent vaccine comprising vaccinal viruses of the four serotypes of dengue fever,in which administration (b) is made between at least 30 days and not more than 12 months following the first administration (a).

The invention belongs to the field of biological products, in particular to a freeze-dried live attenuated hepatitis A vaccine protective agent not containing gelatin or human albumin and used for preventing hepatitis A, and a preparation method for the freeze-dried live attenuated hepatitis A vaccine protective agent. The protective agent comprises trehalose, dextran 40, L-cysteine, arginine, glutamic acid, glycine, magnesium chloride, magnesium sulfate, sorbierite, mannitol and tris(hydroxymethyl)aminomethane. The protective agent with the formula is mixed with a hepatitis A vaccine stock solution to form a semi-finished product, the semi-finished product is packaged and freeze-dried, and virus infectious titers of the vaccine before and after freeze drying and the thermal stability after freeze drying are detected; after the formula is compared with the conventional production formula containing the gelatin, results show that the protective agent has good protective effect, the descent of the virus infectious titers of the vaccine in the freeze drying process is obviously decreased, and the endotoxin content in a finished product is obviously reduced (less than 0.25EU / ml); and after the freeze-dried vaccine with the formula is inoculated into a human body, results indicate that the vaccine has good immune effect and high safety.

Exogenous cDNA capable of expressing interferon″ activity, exogenous interferon″ protein, inducers of endogenous interferon″ protein activity, inducers of endogenous interferon $ protein activity, inducers of endogenous interferon′ activity, or inducers of other immune-enhancing activity can be combined with a vaccine to enhance an immune response. Specifically disclosed are adjuvant and vaccine combinations where the adjuvant comprises a cDNA capable of expressing interferon″ activity, a complex comprising polyriboinosinic-polyribocytidilic acid, or a complex comprising polyriboinosinic-polyribocytidilic acid, poly-L-lysine, and carboxymethylcellulose and where the vaccine is a live vaccine virus derived from a virus causing porcine reproductive and respiratory syndrome disease.

Disclosed is a Madin-Darby canine kidney (MDCK)-derived cell line. The MDCK-derived cell line is derived from MDCK cells deposited under accession number ATCC CCL-34. The MDCK-derived cell line can be prepared by serum-free culture and suspension culture. Preferably, the MDCK-derived cell line has low or no tumorigenicity. The MDCK-derived cell line is preferably selected from MDCK Sky1023, MDCK Sky10234 and MDCK Sky3851. Further disclosed are a culture method for growing the MDCK-derived cells and a method for producing a vaccine virus using the MDCK-derived cells.

The invention discloses a recombination Newcastle vaccine strain rAI4-S1 for expressing infectious bronchitis virus S1 protein and a generating method of the recombination Newcastle vaccine strain rAI4-S1. The conservation number of the recombination Newcastle vaccine strain rAI4-S1 is CGMCC No: 8054. According to the generating method of the recombination Newcastle vaccine strain rAI4-S1, a built reverse genetic manipulation platform of a gene VII type NDV attenuated virus AI4 strain is utilized, the sequence revealed in the SEQ ID NO.7 is inserted into an AI4 strain genome full-length transcription carrier pNDV / AI4, and then the recombination Newcastle vaccine virus genome full-length cDNA clonal pNDV / AI4-S1 containing infectious bronchitis virus S1 genes is obtained. According to a recombination virus obtained through transfection, a chick embryo has high breeding titer, the S1 protein still can be expressed after continuous passage, and the generating method is suitable for large-scale production of vaccines and can be used for processing the vaccines.

The invention relates to a method for inducing a homologous protection against the 4 dengue serotypes in a patient, comprising the sequential administration, to said patient, (i) of a dose of a vaccinal dengue virus of a first serotype and of a dose of a vaccinal dengue virus of a second serotype, and (ii) of a dose of a vaccinal dengue virus of a third serotype and of a dose of a vaccinal dengue virus of a fourth serotype, in which the vaccinal dengue viruses (ii) are administered at least 30 days and at most 1 year after administration of the vaccinal viruses (i).

The invention discloses a method for utilizing Nsp2 gene deletion for constructing a PRRSV gene deletion vaccine virus strain and the application thereof. The method for lowering the toxicity of the PRRSV BJ-4 strain of the invention is that a nucleotide segment with the length of 69nt in a Nsp2 coding region of the PRRSV BJ-4 strain genome is continuously deleted to obtain the virus strain with reduced toxicity; the nucleotide sequence of the 69nt nucleotide segment is shown as the 2795 to 2863 sites from the 5' tail end of GenBank Accession Number AF331831. The Nsp2 of the virus rV63 which is prepared by the method for lowering the toxicity of the PRRSV BJ-4 strain deletes 21 amino acids, which has the potential to develop a marker vaccine and can identify the diagnosis method of the deleted polypeptide. When in the development process of vaccine, the invention can utilizes a reverse genetic technical platform which is already established for carrying out the transformation of GP5 glycosylation sites, thus overcoming the suppression factors which affect the neutralizing epitope and further improving the level of the vaccine-induced neutralizing antibody.

Exogenous cDNA capable of expressing interferon α activity, exogenous interferon α protein, inducers of endogenous interferon α protein activity, inducers of endogenous interferon β protein activity, inducers of endogenous interfereon Γ activity, or inducers of other immune-enhancing activity can be combined with a vaccine to enhance an immune response. Specifically disclosed are adjuvant and vaccine combinations where the adjuvant comprises a cDNA capable of expressing interferon α activity, a complex comprising polyriboinosinic-polyribocytidilic acid, or a complex comprising polyriboinosinic-polyribocytidilic acid, poly-L-lysine, and carboxymethylcellulose and where the vaccine is a live vaccine virus derived from a virus causing porcine reproductive and respiratory syndrome disease.

Disclosed is a Madin-Darby canine kidney (MDCK)-derived cell line. The MDCK-derived cell line is derived from MDCK cells deposited under accession number ATCC CCL-34. The MDCK-derived cell line can be prepared by serum-free culture and suspension culture. Preferably, the MDCK-derived cell line has low or no tumorigenicity. The MDCK-derived cell line is preferably selected from MDCK Sky1023, MDCK Sky10234 and MDCK Sky3851. Further disclosed are a culture method for growing the MDCK-derived cells and a method for producing a vaccine virus using the MDCK-derived cells.

The invention discloses a primer, a probe and a kit for identifying serum I-type Mardivirus gene deletion vaccine, attenuation vaccine and wild virus. The primer and the probe comprise a first pair ofprimer and probe and a second pair of primer and probe, wherein the nucleotide sequence of the first pair of primer and probe is shown as SEQ ID NO. 1 to SEQ ID NO. 3; the nucleotide sequence of thesecond pair of primer and probe is shown as SEQ ID NO. 4 to SEQ ID No. 6. A fluorogenic quantitative PCR reaction is carried out by using the primers and the probes provided by the invention, the serum I-type Mardivirus gene deletion vaccine, attenuation vaccine and wild virus can be identified and diagnosed quickly, accurately, scientifically and objectively, and the immune state of chicken vaccines and the infection progress of wild virus are definite through accurate detection for vaccine virus and wild virus copy number.

The invention relates to a method for inactivating virus in vaccine production, belonging to the field of preparation of biological products. According to the method, the conditional parameters of temperature control, stirring rate, the flow rate of adding formaldehyde solution and the like during the inactivation process of the vaccine production can be improved according to the factors influencing the antigen stability, immunogenicity and antigen recovery rate during the inactivation of vaccine virus liquid are improved to acquire optimal inactivation conditions, the antigen loss during inactivation can be reduced, the antigen structure can be stabilized and the immunogenicity can be improved. According to the method, the quality stability and uniformity of products can be guaranteed, and the production cost can be lowered; the inactivation time can be shortened within 2h from 2.5h, the fatigue of people can be reduced, the production efficiency is improved, the intermediate product during vaccine production is prevented from being stored at room temperature for long time, and the quality of vaccines can be improved indirectly.